Log in

Relevant bibliographies by topics / Nano-formulations for drug delivery

Contents

Journal articles
Dissertations / Theses
Books
Book chapters
Conference papers

Academic literature on the topic 'Nano-formulations for drug delivery'

Author: Grafiati

Published: 6 September 2023

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Nano-formulations for drug delivery.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Nano-formulations for drug delivery"

1

Zhou, Xingli, Ying Hao, Liping Yuan, Sushmita Pradhan, Krista Shrestha, Ojaswi Pradhan, Hongjie Liu, and Wei Li. "Nano-formulations for transdermal drug delivery: A review." Chinese Chemical Letters 29, no. 12 (December 2018): 1713–24. http://dx.doi.org/10.1016/j.cclet.2018.10.037.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Xing, Yue, Peng Lu, Zhifeng Xue, Chunxia Liang, Bing Zhang, Dereje Kebebe, Hongfei Liu, and Zhidong Liu. "Nano-Strategies for Improving the Bioavailability of Inhaled Pharmaceutical Formulations." Mini-Reviews in Medicinal Chemistry 20, no. 13 (August 20, 2020): 1258–71. http://dx.doi.org/10.2174/1389557520666200509235945.

Full text

Abstract:

Pulmonary pharmaceutical formulations are targeted for the treatment of respiratory diseases. However, their application is limited due to the physiological characteristics of the lungs, such as branching structure, mucociliary and macrophages, as well as certain properties of the drugs like particle size and solubility. Nano-formulations can ameliorate particle sizes and improve drug solubility to enhance bioavailability in the lungs. The nano-formulations for lungs reviewed in this article can be classified into nanocarriers, no-carrier-added nanosuspensions and polymer-drug conjugates. Compared with conventional inhalation preparations, these novel pulmonary pharmaceutical formulations have their own advantages, such as increasing drug solubility for better absorption and less inflammatory reaction caused by the aggregation of insoluble drugs; prolonging pulmonary retention time and reducing drug clearance; improving the patient compliance by avoiding multiple repeated administrations. This review will provide the reader with some background information for pulmonary drug delivery and give an overview of the existing literature about nano-formulations for pulmonary application to explore nano-strategies for improving the bioavailability of pulmonary pharmaceutical formulations.

APA, Harvard, Vancouver, ISO, and other styles

3

Vohra, Manisha, Mohammad Amir, Amit Sharma, and Sheetu Wadhwa. "Formulation Strategies for Nose-to-Brain Drug Delivery." Journal of Pharmaceutical Technology, Research and Management 10, no. 1 (May 7, 2022): 87–102. http://dx.doi.org/10.15415/jptrm.2022.101008.

Full text

Abstract:

Background: Neurodegenerative disorders such as Alzheimer’s disease, Parkinson’s disease, Multiple Sclerosis, Dementia, and others are becoming more common globally due to people’s changing lifestyles. Furthermore, the presence of the Blood-Brain barrier and other limitations of oral and other routes of administration makes drug delivery to the brain somewhat tricky. As a result, numerous novel drug delivery systems are being developed for drug administration to the brain. However, nose-to-brain administration is one of the most effective, safe, and non-invasive methods. Purpose: To discuss nose-to-brain delivery as a novel drug delivery system in the treatment of various brain disorders and to provide information about various formulation strategies designed to deliver the drug to the brain effectively. Methods: A preliminary search was conducted in the PubMed, OVID Medline, Embase, ScienceDirect, Web of Science, and Google Scholar databases using keywords such as “Intranasal delivery, nose-to-brain drug transport, formulations for intranasal delivery.” Results: Various marketed formulations for nose-to-brain drug delivery are listed in this review, like naringenin, donepezil, pentamidine, rivastigmine, efavirenz, desvenlafaxine, lamotrigine, haloperidol, nimodipine, olanzapine, valproic acid, ovalbumin, clonazepam, fentanyl citrate, nifedipine in the form of poloxamer chitosan-based nano-formulation, nano-emulsion, chitosan niosomes, chitosan containing emulsion, solid-lipid nanoparticles, PLGA-chitosan nanoparticles, solution, mucoadhesive microemulsion, nanostructured lipid carriers, cationic liposomes, peptide-attached liposomes, multimellar liposomes with their research findings in treating various brain disorders. Conclusion: This review discusses nose-to-brain drug delivery processes, the pathway for its action, advantages over other delivery routes, barriers to this system, and current formulation strategies for nose-to-brain transport.

APA, Harvard, Vancouver, ISO, and other styles

4

Donthi, Mahipal Reddy, Siva Ram Munnangi, Kowthavarapu Venkata Krishna, Ranendra Narayan Saha, Gautam Singhvi, and Sunil Kumar Dubey. "Nanoemulgel: A Novel Nano Carrier as a Tool for Topical Drug Delivery." Pharmaceutics 15, no. 1 (January 3, 2023): 164. http://dx.doi.org/10.3390/pharmaceutics15010164.

Full text

Abstract:

Nano-emulgel is an emerging drug delivery system intended to enhance the therapeutic profile of lipophilic drugs. Lipophilic formulations have a variety of limitations, which includes poor solubility, unpredictable absorption, and low oral bioavailability. Nano-emulgel, an amalgamated preparation of different systems aims to deal with these limitations. The novel system prepared by the incorporation of nano-emulsion into gel improves stability and enables drug delivery for both immediate and controlled release. The focus on nano-emulgel has also increased due to its ability to achieve targeted delivery, ease of application, absence of gastrointestinal degradation or the first pass metabolism, and safety profile. This review focuses on the formulation components of nano-emulgel for topical drug delivery, pharmacokinetics and safety profiles.

APA, Harvard, Vancouver, ISO, and other styles

5

Leong, Moong Yan, Yeo Lee Kong, Kevin Burgess, Won Fen Wong, Gautam Sethi, and Chung Yeng Looi. "Recent Development of Nanomaterials for Transdermal Drug Delivery." Biomedicines 11, no. 4 (April 7, 2023): 1124. http://dx.doi.org/10.3390/biomedicines11041124.

Full text

Abstract:

Nano-engineered medical products first appeared in the last decade. The current research in this area focuses on developing safe drugs with minimal adverse effects associated with the pharmacologically active cargo. Transdermal drug delivery, an alternative to oral administration, offers patient convenience, avoids first-pass hepatic metabolism, provides local targeting, and reduces effective drug toxicities. Nanomaterials provide alternatives to conventional transdermal drug delivery including patches, gels, sprays, and lotions, but it is crucial to understand the transport mechanisms involved. This article reviews the recent research trends in transdermal drug delivery and emphasizes the mechanisms and nano-formulations currently in vogue.

APA, Harvard, Vancouver, ISO, and other styles

6

Nagar, Mohit. "Review on Nano-Emulsion Drug Delivery System and Formulation, Evaluation and Their Pharmaceutical Applications." International Journal Of Health Care And Nursing 2, no. 1 (July 27, 2023): 35–61. http://dx.doi.org/10.55938/ijhcn.v2i1.43.

Full text

Abstract:

Nano-emulsion drug delivery system such as develop to eliminate the limitations with traditional drug administration system. This review provided a good overview of the recent advances in the Nano-emulsion drug delivery system. These are nano-sized submicron emulsions developed to enhanced the circulates of active pharmaceutical ingredients to targeted site. Nano-emulsion is a homogeneous mixture of lipid and aqueous phase and stabilization is obtained through the use of an effective substance such as emulsifying agents. The droplet size has been range between the 50-500 nm. The size and shape of the substance distributed throughout the usual process differentiates of emulsion, micro-emulsion, and nano-emulsion. Nano-emulsion gives a novel dosage form for less water solubility drugs and increases pharmacological activity of drugs. Nano-emulsion is used in the future cosmetic industry, diagnostic testing, drug treatment, and biotechnology. This analysis aims to include brief information on the nano-emulsion, advantages, disadvantages, limitations of nano-emulsion, types of nano-emulsion, components of formulations, surface active agents (Surfactant), preparation methods, characterization methods with strong attention of different pharmaceutical applications of nano-emulsion in a different area such as cancer and tumors therapy, targeted drug delivery, mucosal vaccine, trans-dermal drug delivery system.

APA, Harvard, Vancouver, ISO, and other styles

7

Pandya, Tosha, Kaushika Kaushika Patel, Rudree Pathak, and Shreeraj Shah. "Liposomal Formulations In Cancer Therapy: Passive Versus Active Targeting." Asian Journal of Pharmaceutical Research and Development 7, no. 2 (April 14, 2019): 35–38. http://dx.doi.org/10.22270/ajprd.v7i2.489.

Full text

Abstract:

In Cancer therapy, Nano drug delivery system comprising of Liposomes, are the most successful mode of treatment in present scenario which also has real time clinical application. Recently it is found that the closed bilayer phospholipid vesicles have many technical advantages over the initially used liposomal formulations. The delivery of therapeutics encapsulated in liposomes changes the biological distribution profile and improves the drug therapeutic indices of various drugs. This review article throws light onto many clinical liposomal drug delivery products. The liposome Nano drug delivery by the active and passive targeting is a boon as it can reduce the off-targeting effects. The current development is more focused on the diagnostic and clinical applications. Receptor targeted delivery systems are extensively explored for active targeting. However, these delivery systems are rarely seen in the clinical application because of conjugation chemistry and other implicit hurdles to develop this system.The development of nanocarriers in the cancer treatment have enormous potential in the medical field. Moreover, Immuno liposomes have been used in cancer treatment as attractive drug targeting vehicles. On the other hand, there are many other liposomal drug delivery systems having passive targeting mechanism for cancer treatment which are widely used due to enhanced retention and permeability of formulation. This review majorly focuses on the current challenges encountered in development of liposomal Nano drug delivery systems and its effective development for cancer treatment.

APA, Harvard, Vancouver, ISO, and other styles

8

Kotta, Sabna, Navneet Sharma, Prateek Raturi, Mohd Aleem, and Rakesh Kumar Sharma. "Exploring Novel Strategies for Lipid-Based Drug Delivery." Journal of Nanotoxicology and Nanomedicine 3, no. 1 (January 2018): 1–22. http://dx.doi.org/10.4018/jnn.2018010101.

Full text

Abstract:

Currently, the concept of lipid-based drug delivery systems has gained much interest because of their capability to deliver drugs which dissolve sparingly in water or insoluble in nature. Several methods of lipid-based drug delivery exist, and each method has its own advantages as well as limitations. The primary objective of the formulation development is to improve the bioavailability of the drug. The nano-sized lipid-based drug delivery systems have enough potential to do so. This article addresses the various barriers to the transportation of drugs through certain routes and also the common excipients which used to develop the lipid-based drug delivery systems. It provides a thorough overview of the lipid formulation classification scheme (LFCS) and also deals with several formulation & evaluation aspects of lipid-based drug delivery system. Further, it focuses on the formulations which are already available in the market and their regulatory concerns, respectively.

APA, Harvard, Vancouver, ISO, and other styles

9

Mantry, Shubhrajit, Shubham Shinde, Sahil Shaikh, Sumit Joshi, and Ganesh Dama. "Emerging Implementation of Nano-Suspension Technology for Delivery of Poorly Soluble Drug for the Treatment of Helminths Disease." International Journal of Current Research and Review 14, no. 06 (2022): 43–50. http://dx.doi.org/10.31782/ijcrr.2022.14607.

Full text

Abstract:

Anthelmintics are medications that are used to treat parasitic worm infections. This comprises flat worms like flukes and tapeworms as well as round worms like nematodes. They are critical for human tropical medicine. Nano-suspensions are one of the many applications of nanotechnology. Nano-suspensions are liquid formulations that feature submicron colloidal dispersion of pharmaceutical active component particles stabilised by surfactants. Nano-suspension technology is a novel and cost-effective method for improving the bioavailability of hydrophobic medicines, particularly those that are poorly soluble in aqueous solutions. Nano-suspensions play a significant role in the development of new medication formulations. High pressure homogenizers, emulsion solvent evaporation, melt emulsification technique, and nanoprecipitation are all used to make nano-suspensions. Particle size, zeta potential, drug content, and in vitro drug dissolution were all examined for the nano-suspensions. Poorly soluble drugs can benefit from nano-suspension technology to improve their stability and bioavailability. The bioavailability of nano-suspension was also tested in mice, which showed that the particle size distribution of nano-suspension was considerably affected by bioavailability. The rate of anthelmintic nano-suspension dissolution was substantially higher than that of raw drug powder. In vivo pharmacokinetic characteristics of nano-suspension indicated a substantial increase in Cmax and AUC(0-t) when compared to pure drug. When compared to pure drug bioavailability, anthelmintic nano-suspension had a greater oral bioavailability.

APA, Harvard, Vancouver, ISO, and other styles

10

Gupta, Chetna, Aadya Jaipuria, and Nikesh Gupta. "Inhalable Formulations to Treat Non-Small Cell Lung Cancer (NSCLC): Recent Therapies and Developments." Pharmaceutics 15, no. 1 (December 31, 2022): 139. http://dx.doi.org/10.3390/pharmaceutics15010139.

Full text

Abstract:

Cancer has been the leading cause of mortalities, with lung cancer contributing 18% to overall deaths. Non-small cell lung cancer (NSCLC) accounts for about 85% of all lung cancers. The primary form of therapy used to treat lung cancer still includes oral and systemic administration of drugs, radiotherapy, or chemotherapy. Some patients have to go through a regime of combination therapy. Despite being the only available form of therapy, their use is limited due to the adverse effects, toxicity, and development of resistance over prolonged use. This led to a shift and progressive evolution into using pulmonary drug delivery systems. Being a non-invasive method of drug-administration and allowing localized delivery of drugs to cancer cells, inhalable drug delivery systems can lead to lower dosing and fewer systemic toxicities over other conventional routes. In this way, we can increase the actual local concentration of the drug in lungs, which will ultimately lead to better antitumor therapy. Nano-based systems also provide additional diagnostic advantages during lung cancer treatment, including imaging, screening, and tracking. Regardless of the advantages, pulmonary delivery is still in the early stages of development and various factors such as pharmacology, immunology, and toxicology should be taken into consideration for the development of suitable inhalable nano-based chemotherapeutic drugs. They face numerous physiological barriers such as lung retention and efficacy, and could also lead to toxicity due to prolonged exposure. Nano-carriers with a sustained drug release mechanism could help in overcoming these challenges. This review article will focus on the various inhalable formulations for targeted drug delivery, including nano-based delivery systems such as lipids, liposome, polymeric and inorganic nanocarriers, micelles, microparticles and nanoaggregates for lung cancer treatment. Various devices used in pulmonary drug delivery loaded on various nano-carriers are also discussed in detail.

APA, Harvard, Vancouver, ISO, and other styles

More sources

Dissertations / Theses on the topic "Nano-formulations for drug delivery"

1

Santos, Paulo Antonio Fernandes Gomes. "Transdermal drug delivery using spray formulations." Thesis, University College London (University of London), 2008. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.497653.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Henriques, Neves Vieira R. I. "Volatile formulations for (trans) dermal drug delivery." Thesis, University College London (University of London), 2013. http://discovery.ucl.ac.uk/1393591/.

Full text

Abstract:

Overcoming the excellent barrier properties of the human skin represents the major challenge of this route of delivery. The Metered dose transdermal spray (MDTS®) is a technology developed by Acrux Ltd (AUS). This passive delivery system has the potential to avoid skin irritation. An informed choice of solvents is one of the strategies to design efficient transdermal formulations. Therefore, it is the aim of this thesis to develop optimal volatile formulations and to investigate the enhancement effects of solvents on drug permeation through the skin. A secondary objective is to evaluate the influence of solvent thermodynamic activity on drug permeation and the transport of solvent through skin on drug delivery. Miscibility, solubility, solvent uptake and residence time studies were conducted as a basis for formulation development. The effects of selected solvents on drug permeation were studied using a flow through diffusion cell design, under clinical dosing conditions of use. The influence of formulation related parameters such as solvent dose, supersaturation, combination of solvents and solvent thermodynamic activity, on the amount of ibuprofen permeated through human epidermis was further studied in vitro. The permeation of octyl salicylate, Propylene glycol and polyethylene glycol 200 was monitored by HPLC/UV, GC/MS and LC/MS, respectively, from selected volatile formulations. From these studies, it was found that ibuprofen permeation from all the residual phases studied was solvent dependent. Superior enhancement was obtained using polyethylene glycol 200 followed by propylene glycol, dipropylene glycol and transcutol®. The excipients in which ibuprofen had higher solubility showed a promotion of drug transport. Furthermore, concentration-dependent effect on ibuprofen permeation from solvents was observed. Significant improvements in the permeation of ibuprofen through human skin were achieved using combinations of solvents. The residual phase composed of polyethylene glycol: octyl salicylate (5:1 and 5:10 % (w/v)) were the best solvent/vehicle for ibuprofen permeation. The findings indicate that drug transport appears to be a function not only of the residual phase excipients, but also of the ultimate fate of the excipients after application. Finally, the reported findings demonstrate the potential of volatile formulations to optimise the efficiency of drug delivery to the skin.

APA, Harvard, Vancouver, ISO, and other styles

3

Tandya, Andrian Chemical Sciences &amp Engineering Faculty of Engineering UNSW. "Dense gas particle processing for alternative drug delivery formulations." Awarded by:University of New South Wales. School of Chemical Sciences and Engineering, 2006. http://handle.unsw.edu.au/1959.4/25480.

Full text

Abstract:

Pulmonary and oral drug administrations are usually the preferred methods of delivery of active pharmaceutical ingredients.Generally,pulmonary drug formulations are more attractive compared to oral formulations since they consist of micron-sized powders with high surface area thus having faster onset of action,as well as minimizing the drug dosage and side effects.Oral insulin formulations,if achievable,would provide an alternative to injectable insulin,as the common drawbacks of injectable insulin are the multiple daily injections and the possibility of skin infections at the injection site. In this study,the feasibility of using dense gas particle processing techniques known as the Aerosol Solvent Extraction System (ASES),Gas Anti-Solvent (GAS)and High-Pressure Media Milling (HPMM)for pharmaceutical processing was assessed.The ASEStechnique,utilizing dense ethane,was employed to prepare insulin-lactose formulations for pulmonary administration whilst the GAS and ASES techniques,utilizing dense CO2,were employed to prepare microencapsulated formulations containing insulin and Eudragit?? S100 for oral administration.Furthermore,the HPMM technique,utilizing dense hydrofluocarbon (HFC)134a/227ea,was employed to prepare suspension Metered Dose Inhaler (MDI)formulations containing budesonide and various surfactants. The Fine Particle Fraction (FPF)of processed insulin without the presence of lactose was found to be 44%.In other words,44% of processed insulin delivered to the impactor stages (excluding the throat and neck)has aerodynamic diameter of less than 5??m.With the addition of lactose as carrier,the FPFof the insulin-lactose (1:1w/w)formulation increased to 64%.The increase in FPFwas attributed to the lower density of lactose particles compared to that of insulin particles to produce an intimate mixture with enhanced powder flowability and aerodynamic performance. Proteins for oral delivery should ideally be formulated with acid-resistant polymer as a protective coating to protect against enzymatic degradation in the stomach.Eudragit?? S100,which is insoluble or almost impermeable at pH 1-4and soluble at pH 5-7,was used to prepare oral insulin formulations.The insulin release at pH 3was sustained by the Eudragit?? S100coating and the encapsulation efficiency of insulin??Eudragit?? S100formulations varied between 6% and 24% depending on the initial drug to polymer ratio. One of the major therapies utilizing metered dose inhaler formulations in the treatment of asthma has been studied using the HPMM process.The HPMM process has been demonstrated to be an efficient milling process for the enhancement of the physical stability and aerodynamic performance of budesonide in HFC-134a/227ea propellant formulations.No significant change in physical stability was observed in the formulations for 2 weeks.

APA, Harvard, Vancouver, ISO, and other styles

4

Paulsson, Mattias. "Controlled Release Gel Formulations for Mucosal Drug Delivery." Doctoral thesis, Uppsala : Acta Universitatis Upsaliensis : Univ.-bibl. [distributör], 2001. http://publications.uu.se/theses/91-554-5173-X/.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Subramanian, Sneha. "Proliposome and prosurfactosome formulations for pulmonary drug delivery." Thesis, University of Central Lancashire, 2015. http://clok.uclan.ac.uk/16722/.

Full text

Abstract:

This study aims to compare the efficiency of conventional liposomes and surfactant-enriched vesicles (surfactosomes) using the hydrophilic drug salbutamol sulphate (SBS) and the hydrophobic drug beclometasone dipropionate (BDP) for pulmonary delivery via nebulisation. Initially liposomes and surfactosomes with or without cholesterol were prepared using thin film method and were compared for their VMD, span and drug entrapment. Their drug retention on extrusion through 5µm, 2µm, 1µm and 0.4µm polycarbonate membrane using mini-extruder was also studied. It was observed that liposomes were more stable than surfactosome. Particulate based proliposome technology was also used to study their potential for generating stable and inhalable dispersions. Mannitol was used as the carbohydrate carrier and on hydration; proliposomes and prosurfactosomes have generated liposomes and surfactosomes respectively. The VMD, span and zeta potential of the vesicles, and drug entrapment and drug retention on extrusion were studied. It was seen that lower proportions of SBS were entrapped using proliposome technology; hence, further extrusions through 5µm and 2µm were avoided. In vesicle with BDP, inclusion of cholesterol has decreased the drug entrapment and crystallisation of mannitol was observed. Nebulisation of liposomes and surfactosomes with and without cholesterol was studied using PARI LC sprint air jet nebuliser, Aeroneb pro and Beurer iH50 vibrating mesh nebulisers. Two stage (Twin) impinger was used to study the potential suitability of the generated vesicles for inhalation. VMD, span and zeta potential of vesicles before and after nebulisation was studied. BDP delivery and retention in both stages of the twin impinger was also studied. It was found that surfactosomes without cholesterol delivered maximum BDP to the twin impinger. Nebulisers suitable for all four formulations were also studied. Beurer iH50 delivered maximum BDP via liposomes with and without cholesterol, Aeroneb Pro delivered maximum BDP via surfactosomes with cholesterol to upper impinger while PARI LC sprint delivered maximum BDP via surfactosomes with cholesterol. VMD and span of aerosols generated from all three nebulisers were also studied. Stability of liposomes and surfactosomes prepared using proliposome technology was studied. VMD, span, zeta potential and BDP retention before and after spray drying and freeze drying were investigated. It was concluded that liposomes and surfactosomes were equally stable when spray drying was used whereas liposomes were more stable that surfactosomes when freeze drying was conducted. X-ray diffraction, scanning electron microscopy and transmission electron microscopy were used to analyse the characteristics of proliposomes and prosurfactosomes. A reduction in size and crystallinity was observed after spray drying and freeze drying of the formulations. Stability was also studied on storing proliposome and prosurfactosome in different environmental conditions like 5-6°C, room temperature and 40°C for a period of 3 months. It was concluded that both proliposomes and surfactosomes were most stable in 2-8°Cwhereas least stable in 40°C. Proliposomes were more stable than prosurfactosomes regardless of the storage temperature. Formulation and characterisation of novel prosurfactosomes and comparing it with conventional liposomes for pulmonary drug delivery is the novelty of this thesis.

APA, Harvard, Vancouver, ISO, and other styles

6

Marshall, D. J. "The use of accelerants in topical formulations." Thesis, Open University, 1988. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.234278.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Bandyopadhyay, Sulalit. "Biodegradable Nano-Clusters as Drug Delivery Vehicles." Thesis, Norges teknisk-naturvitenskapelige universitet, Institutt for kjemisk prosessteknologi, 2012. http://urn.kb.se/resolve?urn=urn:nbn:no:ntnu:diva-22677.

Full text

Abstract:

The master thesis has investigated primarily on the synthesis of different polymeric NPs viz PLA (synthesized in house as well as commercial grade), PLGA (commercial) and PCL(synthesized in house, having different functionalities ?COOH, -PEG and their blends) employing flash nano-precipitation technique in a multi inlet vortex mixer (MIVM), previously optimized in the Morbidelli group at ETH. These NPs were characterized using DLS (Dynamic Light Scattering) and Zeta-Sizer to report the variation of the sizes and zeta potentials respectively of the NPs as a function of polymer molecular weight and initial concentration of polymer. The lowest possible sizes of the NPs were then selected for further studies as the overall motivation of the work is to synthesize NCs composed of primary particles and thereafter compare and contrast drug loading, encapsulation efficiencies and release kinetics of a model drug between the two. Ibuprofen (model drug) was loaded into the primary NPs using the MIVM setup, following which drug loading and encapsulation efficiencies were measured using High Performance Liquid Chromatography (HPLC). The release kinetics experiments were performed at 37°C and also studied at room temperature (25°C) and 45°C to evaluate the effect of temperature on release mechanism. The drug-loaded NPs were separated from the free drug in solution at different times using centrifugal filtration. The amount of drug released over time was measured by analyzing these supernatants using HPLC. The MIVM setup is found to produce stable polymeric NPs as small as 50nm and as large as 155nm depending on polymer concentration and nature of polymer. The results indicate that this setup is capable of producing drug loaded NPs with high drug loading efficiencies varying between 75% and 88% differing with polymers. This particular aspect has been established to be both reproducible and valid for a wide range of polymers through subsequent experiments. On the contrary, the release kinetics from almost all the different types of polymeric systems is slow; lasting over several days and moreover, it is not possible to release the entire loaded drug. It is claimed that either the chemical interaction of the polymers with ibuprofen or the location of the drug inside the polymeric NPs is the potential reason for extremely slow release kinetics. It is therefore suggested that further investigation is needed for the same system with another drug, having similar solubility parameters as ibuprofen to confirm the observed behaviour or even a completely different synthesis method for drug loaded polymeric NPs using ibuprofen to substantiate the observed results.

APA, Harvard, Vancouver, ISO, and other styles

8

Abdalghafor, H. M. "Mechanistic studies on topical drug delivery from liquid crystal formulations." Thesis, University College London (University of London), 2014. http://discovery.ucl.ac.uk/1426962/.

Full text

Abstract:

The primary objective of this research was to investigate the possible effects of selected liquid crystal (LC) forming surfactants, namely ArlacelTM 2121, CrodafosTM CES and BrijTM system (BrijTM S721/ BrijTM S2) and selected oils, namely, Arlamol™ PS15E, Crodamol™ OP, Arlamol™ HD on formulation properties. The effects of the different excipients were monitored using the formulations thermal properties, water holding ability and ability to promote the permeation of ibuprofen (IBU and caffeine (CAF)) across silicone membranes. The melting endotherms of the ternary formulations containing 10% w/w Arlamol™ PS15E or Crodamol™ OP, 10% w/w surfactant and 80% w/w water resulted in high melting endotherm (>55˚C). However, the inclusion of 10% w/w Arlamol™ HD in equivalent ternary formulations lowered the melting endotherm to 45-50 ˚C, suggesting a destabilising effect of this oil. In addition, increasing the surfactant content of ternary formulations from 5% w/w to 10% w/w reduced the evaporation time of free water by 10-20 min. However, this change in the water holding ability was not the same for all surfactants. The results ranked the water holding ability of the surfactants as the Brij™ system > CrodafosTM CES > Arlacel™ 2121. The permeation profiles of IBU and CAF across model membranes showed significant enhancement (p <0.05) for both drugs from saturated formulations containing Crodamol™ OP with the Brij™ surfactant system. This was attributed to the uptake of Crodamol™ OP into silicone membrane (22.88%) and the good solubility of both model actives in this oil. In addition, the permeation results suggest that the Brij™ system was interacting with membranes at a greater extent compared with other surfactants. The thesis also investigated the hydration characteristics of the human nail using the Confocal Raman spectroscopy (CRS). The results showed the nail to absorb significant amounts of water (~15% w/w) into the top 5 µm of the nail plate after 10 min of hydration. The absorbed water was lost from the nail in a quick manner of 30 min which agreed with previous reports. The CRS was also used to monitor in vivo deposition of IBU from saturated propylene glycol (PG) solutions under infinite (occluded) conditions. The results were consistent with previous work, showing IBU signal inside the skin to increase consequently with PG content in the applied formulation. These results indicated that CRS can be used as a valid in vivo technique to monitor drug delivery.

APA, Harvard, Vancouver, ISO, and other styles

9

Angel, Aimee B. (Aimee Brigitte) 1977. "A controllable, nano-volumetric, transdermal drug delivery device." Thesis, Massachusetts Institute of Technology, 2002. http://hdl.handle.net/1721.1/89352.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Weight, Alisha K. (Alisha Kessel). "Enhancing pharmaceutical formulations to improve efficacy and delivery of drug molecules." Thesis, Massachusetts Institute of Technology, 2013. http://hdl.handle.net/1721.1/82323.

Full text

Abstract:

Thesis (Ph. D. in Biological Chemistry)--Massachusetts Institute of Technology, Dept. of Chemistry, 2013.
Cataloged from PDF version of thesis.
Includes bibliographical references.
Major impediments to the full utility of current and potential drugs include issues of resistance and delivery. To address these challenges, in this thesis two directions of research were pursued: (1) the use of multivalent polymeric inhibitors to overcome drug resistance in human and avian influenza and (2) low-viscosity, high-concentration protein suspensions for therapeutic antibody, in particular monoclonal antibody (MAb), delivery. (1) Influenza resistance to small molecule neuraminidase (NA) inhibitors is spreading. Little emphasis, however, has been placed on alternative formulations of inhibitors. We investigated the design of multivalent antivirals, wherein small molecule ligands of viral proteins are conjugated via a linker to a linear polymeric backbone. Unexpectedly, we found that a poly-L-glutamine bearing pendant zanamivir (ZA) groups is at least as potent as those containing both ZA and sialic acid (SA). By examining the structure-activity relationship of such monofunctional conjugates, we show that the most potent one has 10% ZA attached to a neutral, high molecular weight backbone through a short alkyl linker. Importantly, we also demonstrate that such a polymer conjugate entirely compensates for weakened binding in and has 2,000-fold enhanced anti-viral potency against, ZA-resistant strains. We further evaluated this optimized inhibitor in vivo and observed that it is an effective therapeutic of established infection in ferrets and reduces viral titers up to 190-fold when used as a combined prophylactic/therapeutic in mice. Additionally, we see no evidence that the conjugate stimulates an immune response in mice upon repeat administration. (2) Typically, high doses of MAb therapeutics are required for clinical effect. Ideally, these MAbs would be delivered by subcutaneous injection of a small liquid volume. Such highly concentrated MAb solutions, however, are far more viscous than the 50 centipose (cP) permitted by the FDA. We evaluated approaches to reduce formulation viscosity by forming protein suspensions. Aqueous suspensions induced by poly(ethylene glycol), precipitating salts, or ethanol actually increased viscosity. However, non-aqueous suspensions of amorphous antibody powders in organic solvents that have s 1 hydrogen atom available for hydrogen-bonding, exhibited up to a 38-fold decrease in viscosity.
by Alisha K. Weight.
Ph.D.in Biological Chemistry

APA, Harvard, Vancouver, ISO, and other styles

More sources

Books on the topic "Nano-formulations for drug delivery"

1

1961-, Osborne David W., Amann Anton H. 1942-, and Colloid and Surface Science Symposium (61st : 1987 : Ann Arbor, Mich.), eds. Topical drug delivery formulations. New York: M. Dekker, 1990.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

2

Pathak, Yashwant, Vijaykumar Sutariya, and Anjali A. Hirani, eds. Nano-Biomaterials For Ophthalmic Drug Delivery. Cham: Springer International Publishing, 2016. http://dx.doi.org/10.1007/978-3-319-29346-2.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Lamprou, Dimitrios, ed. Nano- and Microfabrication Techniques in Drug Delivery. Cham: Springer International Publishing, 2023. http://dx.doi.org/10.1007/978-3-031-26908-0.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Trissel, Lawrence A. Trissel's stability of compounded formulations. 5th ed. Washington, DC: American Pharmacists Association, 2012.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

5

Rajendran, Rajakumari, Hanna J. Maria, Sabu Thomas, and Nandakumar Kalarikkal. Handbook of Research on Nano-Drug Delivery and Tissue Engineering. Boca Raton: Apple Academic Press, 2022. http://dx.doi.org/10.1201/9781003161196.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Ebrahimi, Meysam. Nano Drug Delivery to Brain Cancer: Medicine to help treat cancer. Saarbrücken: LAP LAMBERT Academic Publishing, 2017.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

7

Leong, Thomas Seak Hou, Sivakumar Manickam, Gregory J. O. Martin, Wu Li, and Muthupandian Ashokkumar. Ultrasonic Production of Nano-emulsions for Bioactive Delivery in Drug and Food Applications. Cham: Springer International Publishing, 2018. http://dx.doi.org/10.1007/978-3-319-73491-0.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Osborne, David W., and Anton H. Amann, eds. Topical Drug Delivery Formulations. CRC Press, 1989. http://dx.doi.org/10.1201/9780367803933.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Osbome, David, and Anton Amann, eds. Topical Drug Delivery Formulations. CRC Press, 1989. http://dx.doi.org/10.1201/b14194.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Osborne, David W., and Anton H. Amann. Topical Drug Delivery Formulations. Taylor & Francis Group, 1989.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

More sources

Book chapters on the topic "Nano-formulations for drug delivery"

1

Mudassir, Jahanzeb, and Muhammad Sohail Arshad. "Bioinspired Nano-Formulations." In Drug Delivery Using Nanomaterials, 85–108. Boca Raton: CRC Press, 2021. http://dx.doi.org/10.1201/9781003168584-4.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Batchelor, Hannah. "Rectal Drug Delivery." In Pediatric Formulations, 303–10. New York, NY: Springer New York, 2014. http://dx.doi.org/10.1007/978-1-4899-8011-3_20.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Papazoglou, Elisabeth S., and Aravind Parthasarathy. "Nano Drug Delivery." In BioNanotechnology, 31–45. Cham: Springer International Publishing, 2007. http://dx.doi.org/10.1007/978-3-031-01618-9_3.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Breitkreutz, Jörg, and Joachim Boos. "Drug Delivery and Formulations." In Pediatric Clinical Pharmacology, 91–107. Berlin, Heidelberg: Springer Berlin Heidelberg, 2011. http://dx.doi.org/10.1007/978-3-642-20195-0_4.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

McCray, Scott B., and David K. Lyon. "Green Drug Delivery Formulations." In Green Techniques for Organic Synthesis and Medicinal Chemistry, 613–30. Chichester, UK: John Wiley & Sons, Ltd, 2012. http://dx.doi.org/10.1002/9780470711828.ch23.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Batchelor, Hannah. "Nasal, Ocular and Otic Drug Delivery." In Pediatric Formulations, 273–301. New York, NY: Springer New York, 2014. http://dx.doi.org/10.1007/978-1-4899-8011-3_19.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Murnane, Darragh, and Marc B. Brown. "The Challenges of Paediatric Pulmonary Drug Delivery." In Pediatric Formulations, 253–72. New York, NY: Springer New York, 2014. http://dx.doi.org/10.1007/978-1-4899-8011-3_18.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Wilson, C. G. "Scintigraphic Evaluation of Polymeric Formulations for Ophthalmic Use." In Ophthalmic Drug Delivery, 141–50. New York, NY: Springer New York, 1987. http://dx.doi.org/10.1007/978-1-4757-4175-9_14.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Kwok, Philip Chi Lip, Rania Osama Salama, and Hak-Kim Chan. "Proteins, Peptides, and Controlled-Release Formulations for Inhalation." In Inhalation Drug Delivery, 121–44. Chichester, UK: John Wiley & Sons, Ltd, 2013. http://dx.doi.org/10.1002/9781118397145.ch7.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Patel, Viralkumar F., Darragh Murnane, and Marc B. Brown. "Buccal/Sublingual Drug Delivery for the Paediatric Population." In Pediatric Formulations, 205–15. New York, NY: Springer New York, 2014. http://dx.doi.org/10.1007/978-1-4899-8011-3_15.

Full text

APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Nano-formulations for drug delivery"

1

George, Ashline, and Jerin Cyriac. "Nano particle based drug delivery systems." In 2017 Third International Conference on Advances in Electrical, Electronics, Information, Communication and Bio-Informatics (AEEICB). IEEE, 2017. http://dx.doi.org/10.1109/aeeicb.2017.7972386.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Rautiola, Davin, and Ronald A. Siegel. "Nasal Spray Device for Administration of Two-Part Drug Formulations." In 2019 Design of Medical Devices Conference. American Society of Mechanical Engineers, 2019. http://dx.doi.org/10.1115/dmd2019-3216.

Full text

Abstract:

Intranasal drug delivery is an attractive route to noninvasively achieve a rapid therapeutic effect, avoid first pass metabolism, and bypass the blood brain barrier. However, the types of drugs that can be administered by this route has been limited, in part, by device technology. Herein, we describe a pneumatic nasal spray device that is capable of mixing liquid and solid components of a drug formulation as part of the actuation process during dose administration. The ability to store a nasal spray drug formulation as two separate components can be leveraged to solve a variety of stability issues that would otherwise preclude intranasal administration. Examples of drugs that could be delivered intranasally by utilizing this two-part formulation strategy include biomolecules that are unstable in solution and low solubility drugs that can be rendered into metastable supersaturated solutions. A proof of concept nasal spray device prototype was constructed to demonstrate that a liquid and solid can be rapidly mixed and atomized into a spray in a single action. The primary breakup distance and angle of the spray cone were measured as a function of the function of the propellant gas pressure.

APA, Harvard, Vancouver, ISO, and other styles

3

Aditi and Kushal Qanungo. "Nano particles as drug delivery agents for antitubercular drugs." In INTERNATIONAL CONFERENCE ON HUMANS AND TECHNOLOGY: A HOLISTIC AND SYMBIOTIC APPROACH TO SUSTAINABLE DEVELOPMENT: ICHT 2022. AIP Publishing, 2023. http://dx.doi.org/10.1063/5.0112810.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Da, Anqi. "Applications of Nano-drugs and Tumor Microenvironment Sensitive Nano-drug Delivery Systems." In ICBBS '20: 2020 9th International Conference on Bioinformatics and Biomedical Science. New York, NY, USA: ACM, 2020. http://dx.doi.org/10.1145/3431943.3431944.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Ghosh, Ruby N., Aamir A. Khan, Reza Loloee, and Scott Howard. "Novel Inorganic Nano-scale Phosphorescencent Probe for One or Two-photon Oxygen Imaging." In Optical Molecular Probes, Imaging and Drug Delivery. Washington, D.C.: OSA, 2013. http://dx.doi.org/10.1364/omp.2013.mw5c.4.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Cisek, Richard, Kennedy Brittain, MacAulay Harvey, Saranyan Pillai, Sean D. Christie, and Danielle Tokarz. "Measurement of the Crystalline Structure of Collagen-Like Scaffolds of Otoconia in the Mouse Vestibular System by Second Harmonic Generation Microscopy." In Optical Molecular Probes, Imaging and Drug Delivery. Washington, D.C.: Optica Publishing Group, 2023. http://dx.doi.org/10.1364/omp.2023.om4e.1.

Full text

Abstract:

Polarization-resolved second harmonic generation microscopy was used to elucidate the arrangement of SHG emitters in a collagen-like protein matrix embedded in mammalian inner ear crystals revealing a radial nano- and macro-arrangement.

APA, Harvard, Vancouver, ISO, and other styles

7

Bavali, A., P. Parvin, and R. Karimi. "Blue Spectral Shift of Laser-Induced Fluorescence Due to Suspension of Nano-structures in Rd6G Solution." In Optical Molecular Probes, Imaging and Drug Delivery. Washington, D.C.: OSA, 2015. http://dx.doi.org/10.1364/omp.2015.om4d.2.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Malek, Alaeddin, Hanif Heidari, and Maryam Vali. "Artificial magnetic nano-swimmer in drug delivery." In 2015 22nd Iranian Conference on Biomedical Engineering (ICBME). IEEE, 2015. http://dx.doi.org/10.1109/icbme.2015.7404165.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Mingjun Zhang, Tzyh-Jong Tarn, and Ning Xi. "Micro/nano-devices for controlled drug delivery." In IEEE International Conference on Robotics and Automation, 2004. Proceedings. ICRA '04. 2004. IEEE, 2004. http://dx.doi.org/10.1109/robot.2004.1308128.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Nakano, Masahiro, Hiroyuki Matsuura, Dong-Ying Ju, Takashi Kumazawa, Shinzo Kimura, Yusuke Uozumi, Nobuhito Tonohata, et al. "Drug Delivery System Using Nano-Magnetic Fluid." In 2008 3rd International Conference on Innovative Computing Information and Control. IEEE, 2008. http://dx.doi.org/10.1109/icicic.2008.237.

Full text

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!